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8-Isoprostane Levels in Exhaled Breath Condensate of Pregnant Women Compared to 
Non-Pregnant Women; Is There a Baseline Difference? 
 
Rosemary Szollas 
 
ABSTRACT 
 
This study investigated whether or not there was an overall difference in the 
pulmonary oxidative marker, 8-isoprostane (PGF2-α), found in exhaled breath 
condensate, during pregnancy versus the non-pregnant state.  The utility of this 
information was important secondary to the effect of maternal asthma on pregnancy and 
outcome, as it has been demonstrated in past studies that overall pregnant females with 
asthma have been shown to have an increased risk of exacerbation requiring medical 
intervention. 
The primary goal of this study sought to determine if there is a difference in 
PGF2α levels in the exhaled breath condensate of pregnant versus non-pregnant females.   
In order to achieve this goal a cross-sectional study was performed consisting of two 
groups and were compared to one another. 
A group of 16 healthy, non-pregnant females aged 18-35 years old was compared 
to a group of 6 healthy, pregnant females in their third trimester of pregnancy.  Both 
groups exhaled breath condensate was collected and 8-isoprostane levels determined and 
compared to each other.  Both groups compared did not report a history of environmental 
allergies, asthma, and smoking.  The non-pregnant group showed a mean 8-isoprostane 
 vi 
level of 11.513pg/ml (C.I. 8.7633- 14.263).  The pregnant group showed a mean 8-
isoprostane level of 17.34 pg/ml (C.I. -4.209-38.889).   
Although a crude observable difference between the means of the two groups was 
determined, this pilot study did not show a statistically significant difference between the 
means of the pregnant versus non-pregnant group when they were statistically compared.  
This finding is primarily due to the small sample size of both groups.  A power 
calculation determined that each group would require 25 participants in order to establish 
a statistically significant difference in the 8-isoprostane levels in exhaled breath 
condensate.   
The implication is that a larger scale study is needed in order to conclusively 
determine if there is a statistically significant difference between the exhaled breath 
condensate 8-isoprostane levels in pregnant versus non-pregnant females.   
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Introduction 
 
Isoprostanes 
 
Isoprostanes are derived from membrane lipids via peroxidation with compounds 
such as free radicals and reactive oxygen species1.  This non-enzymatic production of 
isoprostanes catalyzed by free radicals was first described by Morrow and colleagues in 
1990.   It is distinctly different from the classical enyzmatically produced isoprostanes via 
cyclooxygenase (COX) enzymatic pathways (Figure 1).  Since their discovery, the 
usefulness of these compounds as bio-markers in various disease states has been studied.  
In particular, 8-isoprostane or PGF2α, as a marker of oxidative stress in patients with 
asthma has been studied by Montushi and colleagues in 1999.2   Measurement of PGF2α 
has been done by collection of exhaled breath condensates (EBC).  This method of 
collection and analyzing oxidative products in the lung allows for a simple non-invasive 
mean of examining the human lower respiratory tracts3. 
Elevated levels of 8-isoprostanes have shown to correlate with level of disease 
severity in various disease states.  Just why this occurs is not fully understood.  8-
isoprostane produces a number of biological responses, such as smooth muscle 
contraction, vasoconstriction, and platelet activation1.  These responses are thought to be 
a result of an isoprostane receptor binding and subsequent signaling pathway involving 
phospholipase and kinase enzymatic activity resulting in Ca ion channel 
activation1.Various other markers have been found in the breath and typically vary by 
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disease state.  In particular, PGF2α in the exhaled breath condensate, plasma, and serum 
has been found to be elevated in individuals with asthma.  Two separate studies have 
shown PGF2α to be elevated in a group of asthmatic children compared to a group of 
non-pregnant children.4, 5   
Figure 1.  Mechanisms leading to lipid peroxidation in asthma.6 
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Other studies have shown 8-isoprostane levels to be elevated in severe respiratory failure 
in infants.7   Therefore various disease states exist where exhaled breath condensates have 
been showed to be elevated. 
Pregnancy  
Not surprisingly, given its biological responses, 8-isoprostane has also been 
studied in its relationship to a healthy state and various disease states during pregnancy.  
8-isoprostane, as previously discussed, produces smooth muscle contraction, 
vasoconstriction, and platelet activation1.  Preeclampsia is defined as a pregnancy-
dependent syndrome diagnosed on the basis of increased blood pressure and proteinuria.  
Endothelial dysfunction is hallmark of preeclampsia and is central in explaining the main 
features of preeclampsia:  hypertension, edema, proteinuria, and activated homeostasis8.  
For example, plasma concentrations of free 8-isoprostane has been found to be 
significantly greater in a study analyzing levels before delivery in patients with 
preeclampsia than in control subjects.8    It is thought that oxidative lipid derivatives are 
uteroplacental compounds that may cause dysfunctional maternal endothelium.8  
Recently, a study reported an increased content of lipid peroxides in preeclamptic 
decidual placental tissue in preeclamptic patients at delivery compared with controls8.  In 
addition, another study by Moretti and colleagues demonstrated increased markers of 
oxidative stress in preeclamptic women versus uncomplicated pregnancy and non-
pregnant controls by measuring various volatile organic compounds in the exhaled breath 
condensate of these women9.     
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Although levels of 8-isoprostanes have been shown to be elevated in the exhaled 
breath condensate of individuals with asthma, no study to date has measured the levels of 
8-isoprostane in the exhaled breath condensate of pregnant females.  Asthmatic females 
who become pregnant have been demonstrated to be more at risk of low birth weight 
neonates, pre-term delivery, and complications such as preeclampsia, especially in the 
absence of actively managed asthma treated with inhaled corticosteroids.10  These 
mechanisms responsible for changes in asthma with pregnancy, or alterations in 
pregnancy outcomes due to asthma have not been thoroughly explored.      
Asthma is a chronic inflammatory disorder of the airways involving variable 
airflow obstruction and increased airway responsiveness to a variety of stimuli.  The 
airway mucosal inflammatory response in asthma is characterized by increased vascular 
permeability with edema of airway walls, mucus hypersecretion with small airway 
plugging and infiltration with inflammatory cells, typically eosinophils.6  The role of 
oxidant and antioxidant in asthmatic airway inflammation is ill-defined.  Isoprostanes are 
one of the groups of lipid peroxidation products that contribute to the pathophysiological 
changes seen in asthma.6  8-isoprostane, in particularly, has been demonstrated to be 
elevated in certain individuals with various disease states, including asthma.  These 
responses may be partially the result of elevated levels of 8-isoprostane.2  As previously 
stated, 8-isoprostane is a known smooth muscle constrictor, as well as vascular 
constrictor, it has also been demonstrated to cause airway hyperresponsiveness and 
airway obstruction, as well as plasma exudation.11  effects of 8-isoprostane in asthma can 
are listed in Table 1 below. 
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Table 1.  Effects of isoprostanes (8-iso-prostaglandin (PG)F2 ) in asthma6 
 
In vitro/animal models: Human studies: 
Smooth muscle constriction 
22, 23 
8-iso-PGF2  in asthma (plasma 28; breath condensate 
29) 
Airway hyperreponsiveness 
24 
 
Airway obstruction 25 8-iso-PGF2  with asthma severity (plasma 28; breath 
condensate 29) 
Plasma exudation 25   
Vascular constriction 26, 27 8-iso-PGF2  with allergen challenge (urine and 
bronchoalveolar lavage 30)  
 
Given that mechanisms responsible for changes in asthma with pregnancy, or 
alterations in pregnancy outcomes due to asthma have not been thoroughly explored, it 
seems prudent that more research in this are be done as to why this occurs.  It is well 
known that pregnancy alone produces pulmonary changes including increased tidal 
volume leading to increased minute ventilation leading to an increased PAO2 and 
decreased PACO2 and PaCO2.  However, whether or not an increase in oxidative stress 
in the lungs of the pregnant female occurs, also remains unknown.  The effect of 
pregnancy on asthma consensus has remained the same for many years that one-third 
worsens, one-third remain the same and one-third improve.  Regardless, those that 
worsen are at an increased risk of delivering low birth weight neonates, pre-term delivery 
and complications including preeclampsia.  In addition to the increased risk of poor 
outcomes, pregnant females with asthma have an increased risk of an exacerbation 
requiring medical attention which may also increase the risk of a poor outcome.10   
 6 
Since reducing asthmatic inflammation and preventing exacerbations contributes 
to improved outcomes in outcomes for mother and fetus it becomes apparent that studies 
in this area should be focused on understanding changes in airway inflammation in 
pregnant females with asthma, which may lead to more effective treatment and target 
management of pregnant asthmatic females.10   
Exhaled Breath Condensate 
Exhaled breath condensate collection (EBC) is a noninvasive tool to collect breath 
in order to analyze its contents.  The method involves an individual breathing into a 
cooled chamber for approximately 15 minutes.  The condensed breath is then analyzed 
for various substances.12  
Figure 2.  Schematic representation of a EBC collection apparatus13 
 
As previously discussed 8-isoprostane measurements in the exhaled breath 
condensate of pregnant females have not been performed to date.  This method of 
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collection and analyzing oxidative products in the lung allows for a simple non-invasive 
mean of examining the human lower respiratory tracts3.   
The appeal of EBC lies in its ability to non-invasively collect a wide range of 
nonvolatile molecules from the respiratory tract.12  However despite its utility with 
respect to the noninvasive nature EBC portrays, there are drawbacks to analyzing breath 
in this manner.  One of the major problems lies in that of dilution which probably affects 
the concentration of most biomarkers analyzed with in EBC.   In addition, ambient air 
pollutants may influence biomarkers.  Naturally EBC contains mostly water vapor, 
approximately >99.99%.12  Previous studies done in attempts to produce repeatability in 
measuring substances were unsuccessful and showed to be variable between subjects and 
within repeated samples of the same subject.12  
The collection chamber of the device and container that collects, cools, and stores 
the breath is composed either of glass, polystyrene or polypropylene.  The composition 
the EBC may be altered by the adhesive properties of the material from which the 
container is made.  This can be minimized by using a polypropylene container, as less 
adsorption occurs as compared to polystyrene.13   
In addition, collection technique to minimize saliva contamination is one of the 
most important concerns regarding the collection procedure.  Certain substances such as 
nitrite and hydrogen peroxide present in high quantities can contaminate sample data 
interpretation.  This can be minimized by keeping the mouth dry during collection.13 
Table 2 given below illustrates the various advantages and limitations of 
collection and analysis of exhaled breath condensate collection. 
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Table 2.  Advantages and limitations of collections and analysis of exhaled breath 
condensate13 
 
Advantages 
1. Simple, point-of-care intervention 
2. Inclusive rather than intrusive (e.g., healthy children, mechanically ventilated 
  neonates) 
3. Domiciliary 
4. Longitudinal sampling 
5. Nonvolatile compounds associated with pulmonary pathophysiology 
6. Amplified DNA and RNA from prokaryotic and eukaryotic cells 
7. Pharmacokinetics/pharmacodynamics of drugs 
8. Solute clearance 
 
Limitations 
1. Lack of standard breath-sampling method 
2. Not anatomic site specific 
3. Lack of evidence for the origin of the aerosol particles (bronchi   versus terminal 
airways) 
4. Concentration artifact (due to evaporation of samples) 
5. Feasibility and utility of biomarkers unrelated to oxidative stress not tested 
6. Little information on biomarkers of interstitial lung disease 
 
Research Question  
Is there a baseline difference between 8-isoprostane levels in the exhaled breath 
condensate of pregnant women versus those levels in non-pregnant females?  
Hypothesis 
 
The null hypothesis states that there was no difference in the exhaled breath 
condensate oxidative marker PGF2α in pregnant females in their third trimester of 
pregnancy versus non-pregnant females.  The alternative hypothesis states that there was 
a difference between the exhaled breath condensate oxidative marker PGF2α in pregnant 
females in their third trimester of pregnancy versus non-pregnant females.  The utility of 
the study may prove to provide a better understanding of oxidative stress in the pregnant 
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state and may prove to provide a baseline measurement of PGF2α levels in the 
monitoring of airway, and other disease states in pregnancy.   
Goals and Objectives 
The primary objective of this study serves to determine if there is a difference in  
PGF2α levels in the exhaled breath condensate of pregnant versus non-pregnant females.  
In addition, the following goals will be were 1)  To assess the applicability of measuring 
baseline PGF2α levels in pregnant females versus non-pregnant females as a measure of 
oxidative stress 2) To begin to provide an examination of the generalizability of 
measurements of exhaled breath markers to pregnant populations, which may serve as the 
basis for a larger and more in-depth study 3)  To examine whether baseline 8-isoprostane 
levels are appropriately representative of  healthy pregnant females. 
Utility and Significance  
 
This study was unique in that it examined exhaled breath condensate levels in the 
breath of pregnant females which has not been previously performed.  The utility of the 
study proved to provide a better understanding of oxidative stress in the pregnant state 
and proved to provide a baseline measurement of PGF2α levels in the monitoring of 
airway and other disease states in pregnancy.   
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Materials and Methods 
Study Design 
The study design was a cross-sectional design comparing two groups:  a group of 
pregnant women ages 18 to 35 years in their third trimester and a group of non-pregnant 
women in the same age group.  Exposure consisted of pregnancy and non-exposure 
consisted of non-pregnant.  The outcome consisted of levels of PGF2α oxidative marker 
in exhaled breath condensate.  Both groups were screened to exclude those with a recent 
history of upper respiratory infections or smoking and any history of environmental 
allergies or lung disease.  In addition any individual in the pregnant group was excluded 
for any complication of pregnancy, including but not limited to gestational diabetes, 
hyperemesis gravidarum, preeclampsia, hypertension, or any other complication of 
pregnancy. 
Inclusion criteria include female sex, within the age range of 18-35 years, non-
pregnant state (including individuals that have previously been pregnant), and pregnant 
state – specifically within the third trimester of pregnancy.  Informed consent was 
obtained before any testing began. 
Facilities and Equipment 
The participants were seen at the College of Public Health at the University of 
South Florida in the Breath Laboratory (MHH Room 323).  The records were maintained 
in a secured cabinet in this room.  The key to access the laboratory was distributed by the 
University of South Florida only to authorized personnel (obtained through the College of 
Public Health).   
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Exhaled breath condensate samples were collected using Jaeger air condensing 
device (Jaeger, Wuerzburg, Germany 1999).  The Jaeger instrument was located in the 
Breath Lab – MHH room 323.  Samples were stored at approximately -70 degrees 
Celsius in The Breath Lab freezer.  Once samples were ready to be analyzed they were 
removed from the freezer and de-thawed and analyzed using a commercially available 
enzyme linked immunoassay (EIA) kit, ordered from Caymen Chemical.    The EIA kits 
were processed on a 96 well plate and analyzed using a spectrophotometer (μQuant 
Universal Microplate spectrophotometer,2004), which is also available within the Breath 
Lab (MHH Room 323).  All samples were used in their entirety.  
Spirometry was performed using the KoKo spirometry software and devices also 
located within the Breath Lab – Room MHH 323.  Mouthpieces needed for performing 
the testing were disposable and located with in the Breath Lab.    
Participant Recruitment 
Subjects were recruited to volunteer to participate in the study through a one time 
visit to The Breath Lab (Room MHH 323) over a range of months spanning from 
November 2005 to March 2006.  Volunteers were recruited through primarily three 
mechanisms:  1) Advertisements in the form of a poster for non-pregnant and pregnant 
females were displayed in various areas throughout the University of South Florida 
Tampa campus and the Tampa General Hospital Genesis OBGYN clinic (Appendix A,B)  
2)  A mass email targeting female students and staff in the University of South Florida 
health science centers was sent out twice  3)  Researchers personally manned a booth 
located in the Tampa General Hospital Genesis OBGYN clinic to recruit in person.  
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Researchers did not approach volunteers; rather potential subjects voluntarily approached 
the booth. 
Study Subjects and Restrictions 
Healthy pregnant and non-pregnant female subjects were recruited who denied 
any history of environmental allergies, asthma, or other lung diseases.  Also, they must 
not have suffered from any recent upper or lower respiratory tract infections.  Subjects 
must also have no significant smoking history as defined by less than one-half pack-year 
history of smoking, no smoking within the past 2 years, and no significant second-hand 
smoke exposure.  Subjects must refrain from strenuous exercise, food, or drink for one 
hour prior to the test.   
Pregnant subjects were restricted to the third trimester of pregnancy.  Previous 
history of pregnancy or delivery did not exclude subjects.  Gestational dates were taken 
in the medical history portion of the questionnaire form (Appendix A).   
Study Questionnaire and Eligibility 
In order to determine eligibility for potential healthy subjects, subjects were initially 
asked a series of questions.  The questions were asked by telephone when the subject 
called in response to a recruitment flyer or email.  If the potential subject denied any 
previous history of environmental allergy, denied any recent URI infections within the 
past two weeks, denied any chronic diseases and met the age criteria range the participant 
was scheduled for an appointment for testing with in The Breath Lab.   
 Once the subject was met in the Breath Lab the Health Questionnaire was given 
to each subject.  Responses were reviewed by researcher and subject in a private cubicle.  
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Any medications and health problems were reviewed by the researcher.  If subjects met 
inclusion criteria they were invited to then move on to the informed consent 
documentation in order to participate in the study.   
Physical Examination 
All subjects were visually inspected for any cyanosis and clubbing.  Also, 
auscultation of the heart and lungs was performed prior to any breathing tests and at the 
conclusion of each visit.  In auscultation, a stethoscope is used to listen to both heart 
sounds and breath sounds.  Auscultation is routinely and correctly done while disrobed, 
however, for our purposes assessment was done over outer garments.  Pregnant females 
were examined identically to their non-pregnant counterparts; of note, gestational age 
was not assessed on physical examination of pregnant females. 
Exhaled Breath Condensate Collection and Storage 
Data Collection and 8-isoprostane Analysis  
Exhaled breath condensate samples were collected using Jaeger air condensing 
device (Jaeger, Wuerzburg, Germany 1999).  The Jaeger instrument was located in the 
Breath Lab – MHH room 323.  The Jaeger instrumentation was turned on at least 15 
minutes prior to EBC collection in order for adequate cooling time of the collection 
chamber to approximately -30 degrees Celsius.  All valves and collection tubing was 
cleaned with cavicide solution and thoroughly dried prior to use.  A disposable mouth 
piece and nose clip was given to each subject for collection.  Apparatus was assembled 
and subjects were asked to sit in a chair during the fifteen minute collection time.  
Individual were asked to breathe tidally through their mouths, after a nose clip was 
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applied, into the two-way non-re-breathable mouth piece connected to the collection 
chamber portion for a total of fifteen minutes. Subjects were asked to discard any 
excessive saliva produced into a tissue periodically.  Reading material was provided to 
each subject and timer was sent to 15 minutes with alarms at 10 and 5 minutes remaining.  
Subjects were notified that removal of their mouth from the tubing in order to cough, 
sneeze, etc was permitted.  However, subjects were instructed that refraining from 
removing their mouth from the tubing was ideal in order to optimize sample collection.   
After fifteen minutes, collection chamber cups were unscrewed from the chamber and 
breath condensate was immediately transferred to cryo safe storage tubes in a split 
sample using an analytic pipette.  On average two ml of condensate was obtained and 1 
ml stored in each tube.  Samples were then capped and placed in a -70 degree Celsius 
controlled freezer.  Tubes were pre-labeled with subject identification numbers that 
identified samples with individual subjects.  Key sample ID sheets were stored in a 
laboratory workbook in Room MHH 323.  Samples were collected in this manner from 
November 2005 to March 2006. 
8-isoprostane concentrations were measured in pregnant and non-pregnant subject 
samples using a commercially available enzyme immunoassay (EIA) kit (Cayman 
Chemical Company, 8-isoprostane EIA kit model # 516351, Ann Arbor, MI).  The 8-
isoprostane detection limit for the kit is 5 pg/ml.  Normal Plasma 8-isoprostane levels for 
healthy subjects:  40-100 pg/ml (Cayman Chemical), Normal Urine 8-isoprostane levels 
for health subjects:  10-50 pg/ml (Cayman Chemical), exhaled breath condensate 
measurements were not provided by Cayman Chemical.  Exhaled Breath Condensate 8-
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isoprostane levels (two different studies) demonstrated 8-isoprostane levels in a sample 
of 10 children (male) asthmatics  - levels were 9.4-29.5 pg/ml, same study sampled 10 
healthy children (male) – levels were 2.1-3.0 , (Baraldi, et.al., Thorax2003). 
8-isoprostane levels were demonstrated in a sample of 12 healthy children – avg. of 
34.2+/-4.5 pg/ml, compared to a group of 12 asthmatic steroid naïve children – avg of 
56.4+/-7.7.  (Baraldi, et.al., Chest 2003). 
Analyzing the 8-isoprostane kit was done via spectrophotometry (μQuant 
Universal Micro plate spectrophotometer,2004).  Absorbance readings of the EIA kit 
plates were taken according to the manufacturer’s recommendation at 420 nm, 977 nm 
and 900 nm (the higher wavelengths were taken to negate background measurements).   
The EIA 8-isoprostane EIA kit detects 8-isoprostane starting from a concentration of 5 
pg/ml.  The intra and interassay precision for the kit is depicted below (Figure 3).   
Precision which is the component of accuracy that is concerned with the consistency of 
the stability of results is demonstrated in Figure 3 as the degree to which the kit provides 
consistent results from one application to the next.   
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Figure 3.  Cayman chemical 8-isoprostane kit precision curve (Cayman Chemical, kit 
number 516351)  
 
 
 
 
 
The EIA 8-isoprostane laboratory analysis kit works via an Enzyme Linked 
Immunoassay Analysis (ELISA) method.  It is based on the competition between 8-
isoprostane and 8-isoprostane-acetylcholinesterase (AChE) for a limited number of 8-
isoprostane-specific rabbit antiserum binding sites.  So, the concentration of AChE is 
known, and the concentration of 8-isoprostane is unknown.  The reaction between bound 
AChE and the antiserum binding sites produces a yellow color which is absorbed at 412 
nm of light via the spectrophotometer.  Therefore the amount of 8-isoprostane in each 
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sample is inversely proportional to the amount of bound 8-isoprostane AChE, which is in 
turn directly proportional to absorbance.  (See below). 
Absorbance α   {Bound 8-Isoprostane Tracer}  α   1/{8-Isoprostane} 
In order to calculate concentrations from the absorbance values the following manner: 
1. We average the absorbance readings from the NSB wells.  (NSB well = non-
specific binding that occurs even in the absence of antiserum – this artificially 
elevates total antiserum bound). 
2. We average the absorbance reading from the B0 wells (B0 is the max tracer the 
antiserum can bind in the absence of free analyte). 
3. We subtract NSB average from the B0 avg.  This is the corrected B0 or the actual 
real maximum amount bound. 
4. We calculate % B/B0 (%sample or standard bound /maximum bound) for all our 
sample wells.  Once this is done we can use the standard curve to locate the 
%B/B0 and find the corresponding concentration on the x- axis.   
The standard curve was produced via a set of known concentrations of 8-
isoprostane provided in the EIA kit.   
Acquisition of Spirometry 
Spirometry, which is a common clinical method employed in assessing lung 
function, was performed on each subject after collecting exhaled breath condensate.  The 
Koko spirometer was used and calibrated using a standard 3-liter syringe to ambient 
temperature, humidity, and barometric pressure at least once a day on days when 
participants were examined.  The spirometer was additionally re-calibrated when at least 
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six hours had elapsed since the prior calibration or at the discretion of the examiner. The 
raw FEV1 and FVC measurements obtained for each participant were automatically 
compared to their predicted normal values based on age, ethnicity, weight, height, and 
non-smoking status in determining their percent of predicted values using parameters as 
set forth by Crapo et. al.  
The spirometry parameters examined on each study participant included FEV1, 
FVC, FEV1/FVC ratio, and the flow-volume loop.  At least three spirometric 
measurements were obtained on each subject, with at least one flow-volume loop 
showing good effort.  Proper technique was ensured by evaluating the flow-volume curve 
and continuance of the expiratory maneuver for at least six seconds according to ATS 
criteria.  
A nose clip was placed on the subjects’ noses during the study to prevent nasal 
breathing in order to obtain more accurate spirometry results.   Subjects were asked to 
forcibly exhale for at least six seconds through a disposable single-use filter after 
maximal inspiration, followed by another maximal inhalation. The maneuver was 
demonstrated to them to help achieve consistency.   
Any subject with abnormal spirometry measurements was notified of this 
information and advised to consult a healthcare provider and disqualified from the study.  
All subjects with an FEV1/FVC ratio greater than 70% of predicted, FEV1 greater than 
80% of predicted, FVC greater than 70% of predicted, and a normal appearing flow-
volume loop were eligible for the study by spirometric criteria. 
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Adverse effects were unlikely to occur during this phase of the study because 
subjects identified themselves as being in good health, the room was temperature 
controlled, and this phase of the study was brief in duration.  All subjects were seated 
during the spirometry.  In the event that adequate trials could not be obtained in the 
seated position as demonstrated by their flow-volume loops, subjects were asked to stand 
and instructed on safety precautions in the event of symptoms. 
Nonetheless, there was the slight possibility of unusual symptoms such as 
lightheadedness, dizziness, chest pains, palpitations, or shortness of breath during the 
spirometry from overexertion in breathing.  As a precaution, subjects were instructed to 
stop, be seated, and notify the physician examiner immediately if they experienced any 
symptoms at any time.   
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Results 
Study Population Characteristics 
The study population consisted of 22 subjects total; a total of 17 non-pregnant 
females and 5 pregnant females.  Pregnancy dates in terms of weeks ranged from 25-32 
weeks.  The age of the population ranged from eighteen to thirty five years with a median 
age of twenty-three years.  Fourteen of the twenty-two subjects’ occupations were 
students, one a teacher, two waitresses, one coordinator, one scientist, and one lab tech.  
None of the subjects were smokers, and one reported a past smoking history of 2 pack-
year history.  Sixteen of the twenty-two subjects reported no past medical history 
problems.   Nine of the twenty-two subjects reported no use of over the counter 
medications, vitamins or supplements.   
Date of onset of last menstrual cycle was asked and recorded for non-pregnant 
subjects and ranged from 1-28 days with a mean of 14.  Symptoms of cough, phlegm 
production, itchy or runny nose, throat irritation, and chest tightness or pain was asked on 
a four point scale zero = none, one = a little, two = moderate, three = very much.  One 
subject reported throat irritation and rated it as a little.  Two subjects reported cough and 
both rated it as a little.  Five subjects reported phlegm production one reported it as 
moderate, four reported it as a little.  Four subjects reported an itchy or runny nose and 
three reported it as a little, one reported it as moderate.  One subject reported chest 
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tightness or pain and rated it as a little.  Table 3 lists population characteristics, as well as 
Appendix I.   
Table 3.  Demographic characteristics of subjects both pregnant and non 
 
pregnant 
 
Subjec
t 
Occupatio
n 
Preg
nant 
Weeks Menses Smokin
g 
PMH Meds Age 
A1 Student No  14 0 Hernia  30 
A2 Student No  7 0 Insomni
a 
OCP/Ben
/Flex 
22 
A3 Student No  21 0  OCP/MV
I 
23 
A4 Student  No  21 0   25 
A5  No  14 0   20 
A6 Student No  21 0  OCP 23 
A7 Teacher No  28 0   21 
A8 Student No  5 0 Food 
allergy 
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A9 Student No  10 0   24 
A10 Sales No  7 0 Childhd 
asthma 
OCP/Mot
rin 
20 
A11 Student No  21 0   29 
A12 Student No  14 0   28 
A13 Student No  21 0  OCP/Mot
rin 
20 
A14 Waitress No  7 0  Celebrex 18 
A15 Coordinato
r 
No  14 0  Motrin 28 
A16 Student No  1 0 Migrain
e h/a 
Axert 25 
A17 Student No  14 0  OCP 24 
B18 Lab Tech Yes 30 0 0   35 
B19 Scientist Yes 31 0 2  Effexor/
MVI 
33 
B20 Waitress Yes 32 0 0 Gestati
on. 
DM 
Glyb/MV
I 
26 
B21 Student Yes 25 0 0  MVI/ 
Tylen 
20 
B22 Student Yes 25 0 0  MVI 28 
 
 22 
*OCP = oral contraceptive pill, Ben = Benadryl, Flex = Flexeril, MVI = multivitamin  
 
8-Isoprostane Measurements 
The data obtained from analyzing exhaled breath condensate samples from study 
subjects using the 8-isoprostane EIA kit (Cayman Chemical) are given below in graph 
and tabular forms.  The standard curve used to calculate 8-isoprostane concentrations is 
given in Appendix K and L.  Appendix K standard curve shows values prior to removing 
concentrations 500 pg/ml and 250 pg/.  Removal of these concentrations as shown in 
standard curve showed no significant change in concentration calculations for study 
samples.  8-isoprostane concentrations obtained from standard curve were used for 
biostatistical manipulations. 
Table 4.  8-isoprostane concentrations in pregnant and non-pregnant females. 
 
Sample ID #1 – CONC 
(PG/ML) 
#2- CONC 
(PG/ML) 
#3 – CONC 
(PG/ML) 
AVG SD 
A1 4.182 7.298 16.689 9.389 6.511 
A2 16.925 14.207 16.498 15.877 1.462 
A3 8.803 4.374 7.555 6.911 2.284 
A4 18.469 8.700 13.759 13.642 4.886 
A5 - - - - - 
A6 5.372 10.199 7.538 7.703 2.417 
A7 7.311 8.553 5.979 7.281 1.288 
A8 8.048 10.690 11.368 10.035 1.754 
A9 24.335 16.402 15.625 18.788 4.820 
A10 24.421 11.708 13.945 16.692 6.787 
A11 8.048 11.368 10.621 10.012 1.742 
A12 9.837 6.188 12.744 9.590 3.285 
A13 16.901 18.010 11.116 15.342 3.702 
A14 11.533 5.770 9.616 8.973 2.935 
A15 11.389 8.120 7.967 9.159 1.933 
A16 38.277 14.207 13.684 22.056 14.050 
B1 12.971 10.655 5.562 9.730 3.790 
B2 13.502 21.182 10.881 15.188 5.354 
B3 10.805 4.642 6.313 7.253 3.187 
B4 52.832 42.412 48.122 47.789 5.218 
B5 8.349 - 4.954 6.651 2.401 
 
A = NON-PREGNANT,  Mean = 11.51333, B = PREGNANT, Mean = 16.64 
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Concentrations were calculated as a function of the light absorbance of the 8-
isoprostane AChE tracer which is indirectly proportional to the concentration of 8-
isoprostane.   
Given below in figures 4 and 5 are pregnant and non-pregnant concentrations 
obtain from subject exhaled breath condensate samples. 
Figure 4.  8-isoprostane concentrations taken from samples in pregnant females 
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Figure 5. 8-isoprostane concentrations in samples taken from non-pregnant females 
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        Table 5 depicts standard curve values used for concentration calculations.  These 
values were obtained by using known 8-isoprostane concentration standards given in the 
kit.   
Table 5.  Standard concentrations (known) and actual absorbance concentrations detected 
 
STD #  Known 
Conc 
(pg/ml) 
Calc conc 
#1 
(pg/ml) 
Calc 
Conc #2 
(pg/ml) 
Calc 
conc#3 
(pg/ml) 
AVg SD 
1 500.000 - - - - - 
2 250.000 207.790 164.255 166.470 179.505 24.521 
3 125.000 94.526 86.222 141.009 107.253 29.528 
4 62.5000 70.312 82.303 90.090 80.902 9.963 
5 31.300 26.648 28.106 34.964 29.906 4.441 
6 15.600 17.383 11.143 20.294 16.273 4.675 
7 7.800 9.304 6.860 4.870 7.011 2.221 
8 3.900 4.516 5.228 - 4.872 .504 
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Table 6.  Standard concentrations (known) and actual absorbance concentrations detected 
using standard curve without known concentrations 500pg/ml, 250 pg/ml and 125 pg/ml 
STD #  Known 
Conc 
(pg/ml) 
Calc conc 
#1 
(pg/ml) 
Calc 
Conc #2 
(pg/ml) 
Calc 
conc#3 
(pg/ml) 
AVg SD 
1 500.000 - - - - - 
2 250.000      
3 125.000      
4 62.5000   57.886 57.886  
5 31.300 27.485 28.807 34.683 30.325 3.832 
6 15.600 18.450 11.753 21.408 17.204 4.947 
7 7.800 9.700 6.940 4.693 7.111 2.508 
8 3.900 4.296 5.096 - 4.969 .565 
 
Utilizing the standard curve data shown in table 6 above to obtain sample data 
concentrations for subjects did not statistically alter calculated sample concentrations.  
The statistical calculations for 8-isoprostane concentrations of non-pregnant and pregnant 
subjects are given below in Table 8.   
Table 7.  Spirometric data for all subjects tested including pregnant and non-pregnant 
females 
Subject Number FEV1/FVC 
A1  
A2 93% 
A3  
A4 111% 
A5 90% 
A6 98% 
A7 77% 
A8 84% 
A9 91% 
A10 88% 
A11  
A12 94% 
A13 97% 
A14 87% 
A15 96% 
A16 99% 
A17  
B1  
B2 91% 
B3 88% 
B4 94% 
B5 92% 
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No subjects were excluded based on spirometric measurements.  The above 
values do not classify any of the subjects as having an obstructive respiratory component. 
Biostatistical Data for 8-Isoprostane Measurements 
Table 8.  Statistical analysis of mean 8-isoprostane values of 20 subjects tested 
Statistical Measure Non-Pregnant  Pregnant 
N 15 5 
Mean 11.513 17.34 
Median  9.6 9.7 
Mode 10.0  
Standard Deviation 4.966 17.355 
Skewness 0.841 2.039 
Coeff Variation 43.131 100.08 
Sum Weights 15 5 
Sum Observations 172.7 86.7 
Variance 24.659 301.193 
Kurtosis -.2966 4.225 
Std Error Mean 1.282 7.761 
Lower CL of the mean 8.7633 -4.209 
Upper CL of the mean 14.263 38.889 
Lower CL of Std Dev 3.6356 10.398 
Upper CL of Std Dev 7.8317 49.87 
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The data given above show a difference between the means of the two groups.  
The standard deviation of each group is large and demonstrates a largely skewed set of 
data in each of the two sets.  In addition the Lower CL of the means and upper CL for the 
means of each group overlap.   
Performing a T-test on the data in order to determine if the difference between the 
means of the two groups was significant the following data was obtained as shown in 
Table 9 below.   
Table 9.  T-tests used to analyze difference between means of the two groups 
Variable Method Variances DF T value Pr > │t│ 
8-iso  Pooled Equal 18 -1.22 0.2397 
8-iso Satterthwaite Unequal 4.22 -0.74 0.4980 
 
The statistical analysis (Satterthwaite Test for normally distributed data with 
different variances) failed to show a difference between the two means of the data groups 
as the p-value was greater than 0.05.   
The power of the study was calculated and shown to be .518.  
Table 10.  Variables involved in power calculations 
Μ1 
N1=15 
μ2 
N2=5 
σ σ  Α Critical Value Power 
11.513 17.34 4.9659 17.355 0.05 4.84434 .518 
 
Because β = 1 – Power, beta (or the probability of making a type II error) was 
calculated to be equal to 48.2%.    
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Conclusions 
To reiterate, the question of interest has been whether a difference exists in the 
average 8-isoprostane levels between two groups:  Pregnant Females and Non-Pregnant 
Females aged 18-35 years.   
When analyzing the demographic characteristics of the two groups it became 
evident that two subjects in the non-pregnant group could be excluded.  One subject 
reported a history of childhood asthma; another reported a history of food allergies.  Both 
of these subjects were excluded from data calculations.  Subject A10 self reported a 
history of childhood asthma; her 8-isoprostane concentration was 16.692 pg/ml.  The 
subject A8 self reported a history of food allergy; her 8-isoprostane concentration was 
10.035.  All other data collected from subjects was used for calculations. 
The means of the non-pregnant and pregnant groups was 11.513 and 17.34 
respectively.  There is an obvious difference between these two means, but is this 
difference statistically significant?  According to the t-test performed on the two means 
there was not a statistical difference found.  The null hypothesis stated that there was no 
difference in the exhaled breath condensate oxidative marker PGF2α in pregnant females 
in their third trimester of pregnancy versus non-pregnant females.  The alternative 
hypothesis stated that there was a difference between the exhaled breath condensate 
oxidative marker PGF2α in pregnant females in their third trimester of pregnancy versus 
non-pregnant females.  Based on our t-test we must fail to reject the null hypothesis. 
As to why a difference between the two groups was not found could primarily be 
due to the sample size of the study.  Power is largely affected by sample size, that is, if 
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the sample study size is small the study will have insufficient power to detect real 
associations.  Since Power = 1-β the smaller the power the larger the beta (probablility of 
not finding an association in a sample when one exists in the population).    
The standard deviations of both the pregnant group and non-pregnant group were 
large; 4.966 and 17.355 respectively.  This could be in part due to the distribution of 8-
isoprostanes in females, both pregnant and non-pregnant is large in nature.  However, we 
cannot statistically confirm this as our sample size is not large enough for us to conclude 
that we have statistically found a difference between the two means.  
As previously discussed, Staff, et.al. reported an increased content of lipid 
peroxides in preeclamptic decidual placental tissue in preeclamptic patients at delivery 
compared with controls.8  Another study by Moretti and colleagues demonstrated 
increased markers of oxidative stress in preeclamptic women versus uncomplicated 
pregnancy and non-pregnant controls by measuring various volatile organic compounds 
in the exhaled breath condensate of these women9  This study analyzed non-pregnant, 
healthy pregnant and preeclamptic pregnant females.  We sought out to determine if a 
difference exists between baseline levels of 8-isoprostanes between a group of healthy 
pregnant females and non-pregnant females.  This difference between the means of the 
two data sets was shown and is an observed difference, however is not a statistically 
significant difference. 
The implication that the crude means of the two groups indicated an observable 
difference but not a statistically significant difference provides a basis for the need of 
future studies.  Future studies would need to address the necessity of larger sample sizes 
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in each group.  This serves as a challenge as participant recruitment of pregnant females 
in their 3rd trimester was low in this study.   
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Appendix A:  Questionnaire Form 
 
Health Questionnaire 
 
What is your date of birth?___________________________ 
 
Your current age?____________________________ 
 
What is your current  
 
occupation?_________________________________ 
 
Have you ever been pregnant?     YES     NO 
 
 G___P___A___ 
 
Are you currently pregnant?     YES     NO         
 
EDC_________ 
 
When was your last menstrual  
 
period?___________________________________ 
 
Do you have any medical complications related to your pregnancy such as diabetes,  
 
hypertension, morning sickness, etc?   YES   NO   
 
If yes,  
 
what conditions?__________________________________________________ 
 
Do you smoke?     YES     NO 
 
Are you exposed to second hand smoke?     YES     NO 
 
Have you ever smoked?     YES     NO      
 
How many packs per day did you smoke?___________________ 
 
For how many years did you smoke?_______________________ 
 
 
 
 35 
Appendix A (Continued) 
 
When did you quit  smoking? _______________________________________________ 
 
Do you have any medical problems?     YES     NO     Please list them here. 
 
• _________________________________________________________________ 
 
• __________________________________________________________________ 
 
• __________________________________________________________________ 
 
Have you ever had any of the following conditions? 
 
• Chest pain, palpitations, irregular heart beat, or heart disease?     YES     NO 
 
• High blood pressure?     YES     NO 
 
• Asthma, bronchitis, emphysema, or other lung disorder?     YES     NO 
 
Do you see your health care provider on a routine basis for any medical condition?      
 
YES     NO 
 
If so, what?______________________________________________________________ 
 
Do you take any prescription or over-the-counter medications?     YES     NO     If so,  
 
what? 
 
• ________________________________________________________________ 
 
• ________________________________________________________________ 
 
• __________________________________________________________________ 
 
When is the last time you remember being ill?_______________ 
 
What illness did you have?___________________________________________ 
 
To what degree do you have the following symptoms at this time? 
 
Cough: NONE A LITTLE MODERATE
 VERY MUCH 
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Appendix A (Continued) 
 
Phlegm production: NONE A LITTLE MODERATE
 VERY MUCH 
 
Itchy or runny nose: NONE A LITTLE MODERATE
 VERY MUCH 
 
Throat irritation: NONE A LITTLE MODERATE
 VERY MUCH 
 
Chest tightness or pain: NONE A LITTLE MODERATE
 VERY MUCH 
 
Have you been exposed to any gases, dusts, or fumes at home or on the job?     YES      
 
NO 
 
If so, please explain:  
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
_______________________________________________________________________ 
 
 
Post Study Questionnaire 
 
Did you have any concerns about the way the informed consent process was handled?      
 
YES     NO 
 
Did you have any problems with the Health Questionnaire?     YES     NO 
 
Did you have any discomfort or concerns after the physical exam?     YES     NO 
 
Did you have any discomfort or concerns after the nitric oxide test?     YES     NO 
 
Did you have any discomfort or concerns after completing the spirometry?     YES     NO 
 
Please elaborate. Use the back of this page is necessary. 
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Appendix B:  Adult University of South Florida Informed Consent Document 
 
Informed Consent for an Adult 
University of South Florida 
Information for People Being Asked to Take Part in Research Studies 
IRB Study #103718c 
 
Doctors and researchers at University of South Florida (USF) study diseases and other 
health problems people have.  We try to find better ways to help treat these health 
problems. To do this, we need the help of people who agree to take part in a research 
study.  
Title of Research Study:   8-isoprostane levels in exhaled breath condensate of 
pregnant women compared to non-pregnant women, is there a baseline difference? 
Person in Charge of Study:   Rosemary Szollas, M.D. and Stuart Brooks, M.D.; 
Karen Olson, M.D. 
Where the study will be done:  University of South Florida, College of Public 
Health, MHH Room 323 
Who is paying for the study:   Sunshine Education Resource Center  
Should you take part in this study? 
This form tells you about this research study.  You can decide if you want to take part in 
it.   You do not have to take part.  Reading this form should help you decide if you want 
to take part in the study.  If, at any time, you have any questions feel free to ask the 
person explaining this study to you. 
Before you decide: 
• Read this form. 
• Talk about this study with the study doctor or the person explaining the study.  You 
can have someone with you when you talk about the study. 
• Find out what the study is about. 
This form explains: 
• The purpose of this research study. 
• What will happen during this study and what you will need to do. 
• The potential benefits of being in this study, if any. 
• The risks of having problems because you are in this study. 
• The answers to any questions you might have. 
You can ask questions: 
• You may have questions this form does not answer.  If you do, ask the study doctor as 
you go along. 
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• You don’t have to guess at things you don’t understand. Ask the people doing the 
study to explain things in a way you can understand. 
After you read this form, you can: 
• Take your time to think about the information that has been provided to you.  
• Have a friend or family member read the form. 
• Talk it over with your regular doctor. 
It’s up to you.  If you choose to be in the study, then you can sign the form.  If you do 
not want to take part in this study, you do not sign the form.   
Why is this research being done? 
The purpose of this study is to find out if:  
• The purpose of this study is to find out if there is an increased level of 8-isoprostane 
in the exhaled breath condensate of pregnant women.  8-isoprostane is a chemical 
made in the body naturally.  The amount of 8-isoprostane also increases in the lungs 
in some diseases of the lung.  This study will help find out if pregnancy causes an 
increase in the production of 8-isoprostane in the lungs. 
• This study will help find out if 8-isoprostane levels increase during pregnancy and 
help in understanding of how pregnancy affects asthma.  
• To measure 8-isoprostane in the breath we need to collect your exhaled breath.  
Breathing normally into a mouth size tube will do this.  The tube is cooled to a very 
low temperature thereby changing the gas you exhale into a liquid form.  The liquid is 
a suitable way to collect your breath and store it for analyzing. 
Why are you being asked to take part? 
We are asking you to take part in this study because you are a woman of child bearing 
age who is pregnant or who is not pregnant. We need to compare these two groups. 
In order to participate in this study, you need to be between 18 – 35 years of age, a 
non-smoker with no history of asthma, environmental allergies, chronic illness, or 
recent respiratory infection (in the past month). If you are pregnant, you need to be at 
28 weeks gestation or more (as determined by your personal health care provider) 
when you come to the Breath Lab for the study.   
 
How long will you be asked to stay in the study? 
You will be asked to spend about three hours in this study.  
The sample collected from your breath will be stored for a maximum of three months, the  
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analyzing of your sample will take about two hours, you will not be required to be 
present for this portion of the study. 
 One hour includes the time it takes to complete the informed consent process and fill out 
a health questionnaire.  You may choose to take more time to complete the informed 
consent.   
A brief physical examination, collection of exhaled breath condensate and spirometry 
will take about an hour. 
How often will you need to come for study visits? 
A study visit is one you have with the study doctor.  This visit is different than the visits 
you make with your regular doctor.  You will need to come for one study visits in all.   
How many other people will take part? 
About fifty people will take part in this study at USF.    
Will the medical treatment you get from your regular doctor 
change if you take part in this study? 
The kind of treatment you now get from your regular doctor will not change because you 
take part in this study.  The only way that it could potentially change is if we discover a 
medical condition which was not previously diagnosed and your doctor chooses to treat 
you for it. 
You will keep seeing your regular doctor.  Your regular doctor will give you the same 
kind of treatment you would get anyway, whether you take part in the study or not. 
This study includes only healthy women whose only condition requiring treatment should 
be pregnancy.  If you require any other treatment, please do not hesitate to get it.  We 
need you to inform us of any treatment in the month before testing or in the week 
following testing, other than routine prenatal care, because it may affect or ability to use 
your results in this study. 
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What other choices do you have if you decide not to take part 
in this study? 
If you decide you do not want to take part in this study, that is okay.  We are 
performing some simple diagnostic tests. These are probably not necessary for your 
medical care if you are being included in this study. 
If you wanted or needed them done, your personal health care provider could perform 
a physical examination and order spirometry. If you wanted to know the level of 8- 
isoprostane in your breath, you would only be able to have it measured in a study 
such as this one.  It is an experimental study which is not generally available.   
 
How do you get started? 
If you decide to take part in this study, you will need to sign this consent form. 
Then, we will do some screening tests.  Screening tests are tests done to see if you are 
able to be in the study.  Screening tests are different from the actual study procedures.  
The definition of screening is the application of a test to detect a potential disease or 
condition in a person who has no known signs of that disease or condition.  The screening 
tests are done, therefore, prior to the actual study procedures to make sure the researchers 
identify the correct population of individuals to include into the study.   
We will do these screening tests: 
1. The health questionnaire will be used to confirm whether you meet the criteria for 
being involved in this study. In order to be included you need to 
• be a non-smoker 
• be 18 – 35 years of age 
• have no environmental allergies such as hay fever 
• have no chronic illnesses which require routine monitoring or treatment, 
especially asthma or other pulmonary diseases 
• be twenty-eight or more weeks pregnant when you are scheduled to be tested  
OR 
• be non-pregnant, having had a normal menstrual period in the month prior to 
testing 
2. The brief physical examination will include listening to your heart and lungs. In order 
to be 
 included you need to have 
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• clear lung sounds without wheezing, rales, or rhonchi (abnormal lung sounds) 
• a regular heart beat without any murmurs, rubs, or gallops 
There is not a separate visit to complete the screening tests. The results will be available 
once the collected samples are analyzed. Then you and the research team will decide 
whether or not you continue in the study.  
What will you need to do to get ready for this study? 
For one hour prior to your scheduled appointment at the Breath Lab, you will need to 
refrain from eating, drinking, or performing any strenuous exercise such as running, 
weight lifting, or heavy physical labor.   
What will happen during this study?  
You will need to complete five things to complete this study: 
1.  This informed consent document 
2. A health questionnaire 
3. A brief physical exam where we listen to your heart and lungs 
4. Spirometry 
5. The collection of exhaled breath condensate 
If you have not completed the informed consent before you come to the Breath Lab, we 
will complete it at the beginning of your visit. If you agree to participate in the study and 
sign the informed consent, we will proceed. 
The health questionnaire is a short assessment of your health history and any current 
symptoms you may be experiencing. It will be used to collect demographic ( a group of 
characteristics defining human populations) information about you such as your age and 
medical information about your health history and recent symptoms.  
After you complete the health questionnaire, the principal investigator (PI) will listen to 
your heart and lungs. She needs to see if you have wheezing or rhonchi (abnormal breath 
sounds) or an irregular heart beat or murmur. Any of these findings will probably result 
in your withdrawal from the study. 
Next, we will measure how fast you can blow the air out of your lungs and how much air 
you can blow out in a test called spirometry. This test is used routinely to monitor people 
of all ages who have lung disease. We are using it in our study to be certain that you do 
not have any type of undiagnosed lung disease which would affect our results. 
Spirometry takes about as much effort as blowing up a big balloon and is the most 
difficult test to perform in this study. Once again, we need to have three acceptable  
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measurements to complete this test. We will not repeat this test more than eight times 
even if we do not get three acceptable tracings. Most people are able to complete this test 
in five attempts or less. 
You can take your time; you can take a break; or you can stop at any time. 
 Finally, your exhaled breath will be collected and cooled in order to condense (turn from 
a gas to a liquid form) your breath into a liquid for collection and storage.  In order to 
collect your breath condensate we will ask you to breathe as you normally would through 
a disposable tube.  We will ask you to do this for a maximum of fifteen minutes, in order 
to collect an adequate sample amount.  If you need to break to cough, sneeze, or blow 
your nose, or for any other reason you will be asked to remove your mouth from the tube 
and resume breathing through the tube when comfortable once again.  We can collect at 
your pace if necessary.  The time limit is not concrete as it is a recommended time period 
for collection by the manufacturer of the collection device, however if adequate sample 
size is obtained prior to fifteen minutes you may stop if you would like to do so.   
After collection of exhaled breath condensate, we will ask you if you have any questions 
about the tests, any discomfort at all, or any other concerns.  All of these responses will 
be recorded on your health questionnaire. 
 
Will you be paid for taking part in this study? 
Subjects will be offered twenty dollars upon completion of exhaled breath condensate 
collection and for their time spent participating in the study.  
If for any reason a subject is unable to complete the study, the following payment 
schedule will be used: 
1. Completion of exhaled breath condensate collection - $20 
We are not able to reimburse you for additional costs you incur such as parking fees, 
bus or taxi fare, childcare costs, or time away from work. 
What will it cost you to take part in this study? 
 It 
will not cost you anything to be part of the study. 
 You will have to pay for your regular care or any other costs.  Your insurance 
plan should cover your regular costs.  Your insurance plan will not have to pay for 
any study costs. 
What are the potential benefits if you take part in this study? 
We don’t anticipate that you will get any health benefits from taking part in this 
study.  We are performing diagnostic (used to identify disease or conditions) tests 
only; not providing any treatment.  
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You may potentially benefit by learning more about your health as a result of your 
physical examination and testing during this study. 
You may enjoy being part of a study and seeing how it is conducted. 
No matter what, we will learn more about changes in the lungs during pregnancy.  
What we learn may guide further research about asthma and pregnancy. 
What are the risks if you take part in this study? 
There is very little risk that you incur by being part of this study. 
You may experience some discomfort during the collection of the exhaled breath 
condensate or during the spirometry. Spirometry, in particular, requires you to blow 
out as hard and fast as you can. This is something like blowing up a big, stiff balloon. 
You could potentially get an infection in the Breath Lab. This is probably less likely 
than getting an infection at the grocery store. Currently, all subjects being tested are 
healthy subjects. Everyone gets a new, disposable mouthpiece to use. Anything that 
gets contaminated is cleaned according to lab protocol. 
Should you experience any adverse symptoms or event, you will be under the direct 
supervision of a physician at all times during the study. We have emergency 
equipment available and will call for emergency personnel (911) if needed. 
 
Is there any risk to your unborn children if you take part in 
this study? 
This study does not involve any treatment which could affect you unborn child. 
Two of the diagnostic studies which are being performed, physical examination and 
spirometry, are routinely performed in pregnant women who have asthma without any 
adverse outcome. 
The experimental diagnostic study, collection and analyzing levels of exhaled breath 
8-isoprostane, does not expose you to any physical, chemical, or biological hazard 
which could potentially harm you or your unborn child. It is simply a measurement of 
a common constituent in exhaled breath. 
 
What if you get sick or hurt while you are in the study?  
If you need emergency care:  
• Go to your nearest hospital or emergency room right away.  Call 911 for 
help.  You should know that USF does not provide emergency care.  
• Call the study doctors as soon as you can.  They will need to know that you are 
hurt or ill.  Call Rosemary Szollas, M.D., or Stuart Brooks, M.D. at (813) 974- 
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7545.  
• If it is NOT an emergency, and you get hurt or sick while you are taking part 
in this study:  
• Go to your regular doctor.   
• Please inform the study doctors.  They will need to know if you are hurt or ill.  
Call Rosemary Szollas, M.D. or Stuart Brooks, M.D. at (813) 974-7545.  
• The USF Medical Clinics may not be able to give the kind of help you need. You 
may need to get help somewhere else. 
If you are harmed while taking part in the study: 
The state of Florida enjoys what is called "sovereign immunity."  This means that you 
usually cannot sue the state of Florida.  However, the state has waived sovereign 
immunity (agreed to be sued) in certain situations.  One of those situations is if a state 
employee, such as your study doctor or other USF employee, is negligent in doing his or 
her job in a way that harms you during the study.  The money that you might recover 
from the state of Florida is limited in amount. 
You can also call the USF Self Insurance Programs (SIP) at 1-813-974-8008 if you 
think: 
• You were harmed because you took part in this study. 
• Someone from the study did something wrong that caused you harm, or didn’t do 
something they should have done. 
• Ask the SIP to look into what happened.   
Recruitment for this project has been conducted at a Tampa General clinical facility 
therefore participation in this research project will make you subject to the 
following: 
 
ADULT TAMPA GENERAL INJURY STATEMENT 
 
In the event you suffer an injury or illness as a result of participating in this research 
study, please be aware that immediate, short-term medical treatment for the injuries or 
illness will be available to you from Tampa General Hospital.  The cost of the medical 
treatment will be billed to you to the extent not covered by your insurance company or 
government program or study sponsor.  No other compensation will be offered.  You are 
not giving up any legal rights by signing this form.  If you believe you have experienced 
a reaction to the study medication or have been injured as a result of research procedures 
performed at Tampa General Hospital, please contact the Department of Risk 
Management at (813) 844-7666. 
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What will we do to keep your study records private? 
Federal law says we must keep your study records private.  We have made prior 
arrangements to do this. 
To maintain subject confidentiality, each subject will be given a random three digit 
subject number which will be recorded on the informed consent document and 
compiled in a master list of all subjects.  This number will be the only identifier listed 
on the health questionnaire, the data collection form, the appointment list, spirometry 
report, and sample storage tubes.   Without the informed consent documents or the 
master list, it will not be possible to link any confidential information to the subject. 
The informed consent document and a master list of subjects will be kept in a locked 
file cabinet in the Breath Lab or in the Occupational Medicine Residency Office. 
Access to this material will only be available the investigators in the study.  
Questionnaires and recorded data from the study will be kept in a locked file cabinet 
in the Breath Lab or in the Occupational Medicine Residency office separate from the 
informed consent documents and the master list whenever they are not in direct 
possession of the investigators. These documents will not contain any information 
which could, by itself, link them to you. 
However, certain people may need to see your study records.  By law, anyone who looks 
at your records must keep them completely confidential.  The only people who will be 
allowed to see these records are: 
The medical staff who are taking care of you. 
Certain government and university people who need to know more about the study.  For 
example, individuals who provide oversight on this study may need to look at your 
records.  These include the University of South Florida Institutional Review Board (IRB) 
and the staff that work for the IRB.  Other individuals who work for USF that provide 
other kinds of oversight may also need to look at your records.  Other individuals who 
may look at your records include:  the Florida Department of Health, people from the 
Food and Drug Administration (FDA) and the Department of Health and Human Services 
(DHHS)  (This is done to make sure that we are doing the study in the right way.  They 
also need to make sure that we are protecting your rights and your safety.) 
We may publish what we find out from this study.  If we do, we will not let anyone know 
your name.  We will not publish anything else that would let people know who you are.   
What happens if you decide not to take part in this study? 
You should only take part in this study if you want to take part.   
If you decide not to take part: 
• You will not be in trouble or lose any rights you normally have.  
• You will still have the same health care benefits. 
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• You can still get your regular treatments from your regular doctor. 
What if you join the study and decide you want to stop later 
on? 
You can decide after signing this informed consent document that you no longer want 
to take part in this study.  If you decide you want to stop taking part in the study, tell 
the study staff as soon as you can. 
• You can stop at any time without any adverse outcome.   
• If you decide to stop, you can continue getting care from your regular doctor.  
Are there reasons we might take you out of the study later 
on? 
Even if you want to stay in the study, there may be reasons we will need to take you 
out of it.   You may be taken out of this study if: 
• We find out it is not safe for you to stay in the study.  
• You experience a change in your health which is inconsistent with the study 
criteria. 
• You miss your appointment at the Breath Lab twice without calling ahead of time 
to reschedule. 
You can get the answers to your questions. 
If you have any questions about this study, call Rosemary Szollas, M.D. at (813) 974-
7545. 
If you have questions about your rights as a person who is taking part in a study, call the 
Division of Research Compliance of the University of South Florida at (813) 974-9343. 
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Signatures for Consent to Take Part in this Research Study 
It is up to you to decide whether you want to take part in this study.  If you want to take 
part, please read the statements below and sign the form if the statements are true. 
I freely give my consent to take part in this study.  I understand that this I am agreeing 
to take part in research.  I have received a copy of this consent form to take with me. 
 
____________________________________________     ___________ 
Signature of Person Taking Part in Study 
 
 Date 
 
____________________________________________   
Printed Name of Person Taking Part in Study 
 
Optional - Witness 
____________________________________________     ___________ 
Signature of Witness Date 
____________________________________________   
Printed Name of Witness 
 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can 
expect. 
I hereby certify that when this person signs this form, to the best of my knowledge, he 
or she understands: 
What the study is about. 
What needs to be done. 
What the potential benefits might be.  
What the known risks might be.   
I also certify that he or she does not have any problems that could make it hard to 
understand what it means to take part in this study. This person speaks the language 
that was used to explain this study. 
This person reads well enough to understand this form or, if not, this person is able to  
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hear and understand when the form is read to him or her. 
This person does not have a medical problem that makes it hard to understand what is 
being explained and can, therefore, give informed consent.   
This person is not taking drugs that make it hard to understand what is being 
explained and can, therefore, give informed consent.   
 
____________________________________________     ___________ 
Signature of Person Obtaining Informed Consent               Date 
 
__________________________________________________ 
Printed Name of Person Obtaining Informed Consent 
 
Optional - Witness 
____________________________________________     ___________ 
Signature of Witness Date 
____________________________________________   
Printed Name of Witness 
Addendum to the Consent 
Consent to take and store additional samples. 
We are asking you to allow us to take and store additional samples of your exhaled breath 
for use in the future.  These samples may be used for a variety of purposes.   
This means we will take some of your exhaled breath and cool it in order to collect the 
liquid form of your breath.  We will then freeze this small amount of liquid (about half of 
a teaspoon) at below freezing temperatures in order to stabilize the compounds within 
your breath.  Once we are capable of analyzing your sample within the breath lab we will 
de-thaw the sample and utilize it in a chemical assay kit that determines the concentration 
of 8-isoprostane within your breath.  Your entire sample collected will be used for this 
technique and we will not discard any of the sample.   
When you sign this below, you are agreeing to let us store and use your exhaled breath 
condensate for future research studies.   
We may use these samples to help us: 
? Determine if 8-isoprostane is elevated in the exhaled breath condensate of 
pregnant women. 
? Help us with understanding how pregnancy affects asthma. 
____ I give my consent to provide my exhaled breath condensate for that purpose. 
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____ I do not give my consent to my exhaled breath condensate for that purpose. 
____________________________________________     ___________ 
Signature of Person Taking Part in Study Date 
____________________________________________  
Printed Name of Person Taking Part in Study 
 
Optional - Witness 
____________________________________________     ___________ 
Signature of Witness Date 
____________________________________________   
Printed Name of Witness 
 
